PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
DNA vs. WBA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between DNA and WBA is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

DNA vs. WBA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ginkgo Bioworks Holdings, Inc. (DNA) and Walgreens Boots Alliance, Inc. (WBA). The values are adjusted to include any dividend payments, if applicable.

-60.00%-40.00%-20.00%0.00%20.00%40.00%AugustSeptemberOctoberNovemberDecember2025
-5.30%
16.88%
DNA
WBA

Key characteristics

Sharpe Ratio

DNA:

-0.72

WBA:

-0.65

Sortino Ratio

DNA:

-1.16

WBA:

-0.82

Omega Ratio

DNA:

0.87

WBA:

0.90

Calmar Ratio

DNA:

-0.77

WBA:

-0.44

Martin Ratio

DNA:

-1.11

WBA:

-0.90

Ulcer Index

DNA:

69.11%

WBA:

43.40%

Daily Std Dev

DNA:

105.52%

WBA:

59.77%

Max Drawdown

DNA:

-99.10%

WBA:

-87.93%

Current Drawdown

DNA:

-98.19%

WBA:

-81.13%

Fundamentals

Market Cap

DNA:

$622.50M

WBA:

$11.17B

EPS

DNA:

-$12.89

WBA:

-$9.92

Total Revenue (TTM)

DNA:

$183.20M

WBA:

$150.41B

Gross Profit (TTM)

DNA:

$120.09M

WBA:

$26.53B

EBITDA (TTM)

DNA:

-$338.01M

WBA:

-$12.13B

Returns By Period

In the year-to-date period, DNA achieves a 10.29% return, which is significantly lower than WBA's 34.19% return.


DNA

YTD

10.29%

1M

7.44%

6M

-5.37%

1Y

-77.62%

5Y*

N/A

10Y*

N/A

WBA

YTD

34.19%

1M

29.07%

6M

19.96%

1Y

-38.85%

5Y*

-21.28%

10Y*

-13.26%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

DNA vs. WBA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DNA
The Risk-Adjusted Performance Rank of DNA is 1111
Overall Rank
The Sharpe Ratio Rank of DNA is 1111
Sharpe Ratio Rank
The Sortino Ratio Rank of DNA is 88
Sortino Ratio Rank
The Omega Ratio Rank of DNA is 1111
Omega Ratio Rank
The Calmar Ratio Rank of DNA is 55
Calmar Ratio Rank
The Martin Ratio Rank of DNA is 1919
Martin Ratio Rank

WBA
The Risk-Adjusted Performance Rank of WBA is 1717
Overall Rank
The Sharpe Ratio Rank of WBA is 1313
Sharpe Ratio Rank
The Sortino Ratio Rank of WBA is 1313
Sortino Ratio Rank
The Omega Ratio Rank of WBA is 1414
Omega Ratio Rank
The Calmar Ratio Rank of WBA is 2020
Calmar Ratio Rank
The Martin Ratio Rank of WBA is 2626
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

DNA vs. WBA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Ginkgo Bioworks Holdings, Inc. (DNA) and Walgreens Boots Alliance, Inc. (WBA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for DNA, currently valued at -0.72, compared to the broader market-2.000.002.004.00-0.72-0.65
The chart of Sortino ratio for DNA, currently valued at -1.16, compared to the broader market-4.00-2.000.002.004.00-1.16-0.82
The chart of Omega ratio for DNA, currently valued at 0.87, compared to the broader market0.501.001.502.000.870.90
The chart of Calmar ratio for DNA, currently valued at -0.77, compared to the broader market0.002.004.006.00-0.77-0.47
The chart of Martin ratio for DNA, currently valued at -1.11, compared to the broader market-10.000.0010.0020.0030.00-1.11-0.90
DNA
WBA

The current DNA Sharpe Ratio is -0.72, which is comparable to the WBA Sharpe Ratio of -0.65. The chart below compares the historical Sharpe Ratios of DNA and WBA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.40-1.20-1.00-0.80-0.60AugustSeptemberOctoberNovemberDecember2025
-0.72
-0.65
DNA
WBA

Dividends

DNA vs. WBA - Dividend Comparison

DNA has not paid dividends to shareholders, while WBA's dividend yield for the trailing twelve months is around 7.99%.


TTM20242023202220212020201920182017201620152014
DNA
Ginkgo Bioworks Holdings, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
WBA
Walgreens Boots Alliance, Inc.
7.99%10.72%7.35%5.13%3.63%4.64%3.05%2.46%2.13%1.78%1.64%1.71%

Drawdowns

DNA vs. WBA - Drawdown Comparison

The maximum DNA drawdown since its inception was -99.10%, which is greater than WBA's maximum drawdown of -87.93%. Use the drawdown chart below to compare losses from any high point for DNA and WBA. For additional features, visit the drawdowns tool.


-100.00%-95.00%-90.00%-85.00%-80.00%-75.00%-70.00%AugustSeptemberOctoberNovemberDecember2025
-98.19%
-72.01%
DNA
WBA

Volatility

DNA vs. WBA - Volatility Comparison

Ginkgo Bioworks Holdings, Inc. (DNA) has a higher volatility of 33.83% compared to Walgreens Boots Alliance, Inc. (WBA) at 27.65%. This indicates that DNA's price experiences larger fluctuations and is considered to be riskier than WBA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%AugustSeptemberOctoberNovemberDecember2025
33.83%
27.65%
DNA
WBA

Financials

DNA vs. WBA - Financials Comparison

This section allows you to compare key financial metrics between Ginkgo Bioworks Holdings, Inc. and Walgreens Boots Alliance, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab